Teva Pharmaceutical Industries (NYSE: TEVA) has released its Q3 2026 Aide Memoire, a document designed to assist investors ahead of the company's third-quarter financial results. The memo compiles public information from previous disclosures and management commentary to provide context for the upcoming earnings report.

The Aide Memoire is now available on the "Investors" page of Teva's website. It serves as a preparatory resource for the Q3 2026 results, which are scheduled for release on Tuesday, November 3, 2026. The document draws from Teva’s prior results, previous management outlooks, and data from select independent sources.

Earnings Schedule and Access

Teva plans to publish its press release at 7:00 am ET on November 3, followed by a conference call and live webcast at 8:00 am ET on the same day. Investors and analysts can access the results via the company's investor relations website. A replay of the webcast will be available within 24 hours after the conclusion of the call.

Document Details

Participants are required to register in advance to obtain local or toll-free phone numbers and personal pins for the conference call. The live webcast will be hosted on Teva's investor relations portal. Following the event, a recorded version of the presentation will be accessible on the same platform.

About Teva

Teva Pharmaceutical Industries describes itself as transforming into a leading innovative biopharmaceutical company supported by a generics business. The firm operates in neuroscience and immunology, offering complex generic medicines, biosimilars, and pharmacy brands globally.

Oppenheimer initiated coverage on Teva Pharmaceutical Industries (NYSE: TEVA) with an Outperform rating. Analyst Les Sulewski announced a price target of $50 for the pharmaceutical company.

The initiation reflects the firm's assessment of Teva's current market position and future prospects within the healthcare sector.